
The combined use of tissue and liquid biopsy maximizes biomarker detection rates. This comprehensive approach increases the likelihood of identifying clinically relevant alterations that may guide targeted treatment decisions.
In a study by Wade T. Iams et al., liquid biopsy identified variants that were not detected through solid tumor analysis in 9% of patients with metastatic pan-cancer disease (N=1,448).(¶)
Similarly, the ROME study (Marchetti et al., 2025) demonstrated that the integrated evaluation of tissue and liquid biopsy helped minimize missed actionable variants. When combined with recommendations from a Molecular Tumor Board, this approach contributed to improved treatment outcomes.(¶)
Test Contents:
See Focus CGP
See Focus 77 Liquid
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, 34394 Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00